Selective reporting in trials of high risk cardiovascular devices: Cross sectional comparison between premarket approval summaries and published reports

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Chang, Lee ^a   Dhruva, Sanket S ^b   Chu, Janet ^c   Bero, Lisa A ^d   Redberg, Rita F ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR EQUIPMENT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CORONARY STENT; CROSS-SECTIONAL STUDY; DEVICE APPROVAL; DEVICE COMPARISON; DEVICE SAFETY; FOOD AND DRUG ADMINISTRATION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; CLINICAL TRIAL (TOPIC); HEART ASSIST DEVICE; HUMAN; PUBLISHING; UNITED STATES;

CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DEVICE APPROVAL; HEART-ASSIST DEVICES; HUMANS; PEER REVIEW; PUBLICATION BIAS; PUBLISHING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84936849945     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2613     Document Type: Article

References (28)

1. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006;295:1901-6.
2. Premarket Approval. US Food and Drug Administration. www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYour Device/PremarketSubmissions/PremarketApprovalPMA/default.htm
3. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA 2009;302:2679-85.
4. Chen CE, Dhruva SS, Redberg RF. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval. JAMA 2012;308:1740-2.
5. Rising K, Baccheti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:1561-70.
6. Ross JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM. Time to publication among completed clinical trials. JAMA Intern Med 2013;173:825-8.
7. "Talent Thoracic Stent Graft System" summary of safety and effectiveness data. US Food and Drug Administration. www.accessdata.fda.gov/cdrh-docs/pdf7/P070007b.pdf
8. Fairman RM, Criado F, Farber M, et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: the VALOR trial. J Vasc Surg 2008;48:546-54.
9. Gordon D, Taddei-Peters W, Mascette A, et al. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 2013;369:1926-34.
10. Ross JS, Tse T, Zarin DA, et al. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 2012;344:d7292.
11. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-260.
12. "XIENCE V Rapid Exchange (RX) Everolimus Eluting Coronary Stent System" summary of safety and effectiveness data. US Food and Drug Administration. www.accessdata.fda.gov/cdrh-docs/pdf7/P070015b.pdf
13. Stone GW, Midei M, Newman W, et al. Comparison of an everolimuseluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.
14. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized clinical trials. JAMA 2009;302:977-84.
15. Dwan K, Altman DG, Cresswell L, et al. Comparison of protocols and registry entries to published reports for randomized controlled trials. Cochrane Database Syst Rev 2011;1:MR000031.
16. "7F Freezor Cardiac Cryoablation Catheter and CCT.2 CryoConsole System" summary of safety and effectiveness data. US Food and Drug Administration. www.accessdata.fda.gov/cdrh-docs/pdf2/P020045b.pdf
17. Friedman PL, Dubuc M, Green MS, et al. Catheter cryoablation of supraventricular tachycardia: results of the multicenter prospective "frosty" trial. Heart Rhythm 2004;1:129-38.
18. Vedula S, Bero L, Scherer R, Dickersin K. Outcome reporting in industry-sponsored trials of Gabapentin for off-label use. N Engl J Med 2009;361:1963-71.
19. Vedula S, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of Gabapentin. PLoS Med 2013;10:e1001378.
20. Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in ClinicalTrials.gov and high-impact journals. JAMA 2014;311:1063-5.
21. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. N Engl J Med 2012;366:848-55.
22. Basu S, Hassenplug JC. Patient access to medical devices - a comparison of U.S. and European review processes. N Engl J Med 2012;367:485-8.
23. Wolfe N, Gotzsche PC, Bero L. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev 2013;2:31.
24. Schroll JB, Bero L, Gotzsche P. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:f2231.
25. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012;9:e1001201.
26. Eichler H-G, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? A view from regulators. PLoS Med 2012;9:e1001202.
27. Torjeson I. European drug agency backtracks on plan to give researchers access to clinical trial reports. BMJ 2014;2014:348:g3432.
28. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol 2015;68:102-7.